Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients.-Reference-Cited by-同舟云学术

Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:e13500-e13500
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Orlov Sergey V.¹,Burdaeva Olga N.²,Nechaeva Marina P.²,Kopp Mikhail V.³,Kotiv Bogdan N.⁴,Sheveleva Ludmila P.⁵,Gladkov Oleg A.⁶,Khorinko Andrey V.⁷,Prokopenko Tatiana I.⁷,Shapovalova Julia S.⁸,Jelvakova Irina A.⁸,Kovalenko Nadezhda V.⁹,Stroyakovsky Daniil L.¹⁰,Pecheniy Aleksandr P.¹¹,Ivanov R.¹²,Filon Olga V.¹²,Tjulandin Sergei¹³

Affiliation:

1. Department of Thoracic Oncology, St. Petersburg State Medical University, St. Petersburg, Russia

2. Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russia

3. Samara Regional Clinical Oncology Dispensary, Samara, Russia

4. State Educational Institution High Professional Education Military Medical Academy named after S.M.Kirov, St Petersburg, Russia

5. Volgograd Regional Clinical Oncological Dispensary, Volgograd, Russia

6. Chelyabinsk Regional Clinical Oncological Center, Chelyabinsk, Russia

7. Perm Regional Oncology Dispensary, Perm, Russia

8. Railroad Clinical Hospital, Chelyabinsk, Russia

9. Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russia

10. Moscow City Oncology Hospital, Chemotherapy Department, Moscow, Russia

11. Orel Oncology Dispensary, Orel, Russia